Doma and its affiliate, Xadcera, officially received IND clearance from U.S. FDA for their first bispecific ADC asset, DM001.
Doma officially received IND clearance from U.S. FDA for their first bispecific ADC asset, DM005.
DM001, a Class 1 innovative drug independently developed by Doma's subsidiary, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., an EGFR/TROP2 bispecific antibody-drug conjugate (ADC) for injection, has received the Clinical Trial Approval Notice in China.
DM005, a Class 1 innovative drug independently developed by Doma, an EGFR/c-MET bispecific antibody-drug conjugate (ADC) for injection, has had its new drug clinical research application approved by the National Medical Products Administration (NMPA) of China, and patient enrollment has begun in China. On August 29 and September 11, 2024, the drug also received approvals from the U.S. FDA and the Australian TGA, respectively, to initiate Phase I clinical studies. The first patient dosing in the U.S. was completed on November 19, 2024.
Establishment of Doma's first incubation company
Establishment of Doma's incubation company
On June 1, 2022, Doma Biopharmaceutical (Suzhou) Co., Ltd. announced the completion of a round A financing of 950 million rmb.
